{"organizations": [], "uuid": "601b5525002e8299fd5c759c95b5418182165dd3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180328.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ose-immunotherapeutics-fy-revenue/brief-ose-immunotherapeutics-fy-revenue-up-at-6-7-million-euros-idUSW8N1A7023", "country": "US", "domain_rank": 408, "title": "BRIEF-Ose Immunotherapeutics FY Revenue Up At 6.7 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.98, "site_type": "news", "published": "2018-03-29T00:16:00.000+03:00", "replies_count": 0, "uuid": "601b5525002e8299fd5c759c95b5418182165dd3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ose-immunotherapeutics-fy-revenue/brief-ose-immunotherapeutics-fy-revenue-up-at-6-7-million-euros-idUSW8N1A7023", "ord_in_thread": 0, "title": "BRIEF-Ose Immunotherapeutics FY Revenue Up At 6.7 Million Euros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:\n* TEDOPI: REDEPLOYMENT OF THE PHASE 3 CLINICAL PHASE IN EARLY 2018\n* TEDOPI: PHASE 2 TRIAL IN PANCREATIC CANCER INITIATION IS EXPECTED IN 2018\n* OSE-172: ENTRY INTO CLINICAL PHASE PLANNED IN 2018\n* FY OPERATING LOSS EUR 12.6 MILLION VERSUS PROFIT EUR 17.5 MILLION YEAR AGO\n* FY NET LOSS EUR 10.5 MILLION VERSUS PROFIT EUR 20.7 MILLION YEAR AGO\n* CASH AVAILABLE AS OF DECEMBER 31, 2017 OF EUR 12.5 MILLION VERSUS EUR 17.8 MILLION YEAR AGO\n* FY REVENUE EUR 6.7 MILLION VERSUS EUR 383,000 YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-29T00:16:00.000+03:00", "crawled": "2018-03-29T15:55:16.000+03:00", "highlightTitle": ""}